Background. Screening strategies based on interferon-γ release assays in tuberculosis contact tracing may reduce the need for preventive therapy without increasing subsequent active disease.
put on treatment without increasing subsequent active tuberculosis [7] . Although the use of a 2-step approach-using an IGRA to confirm the positivity of a TST-is supported by several cost-effectiveness analyses [9] , only 2 studies were carried out to evaluate the safety of this strategy, with conflicting results [10, 11] .
In this clinical trial, we assessed the noninferiority to traditional testing of a sequential strategy using the TST followed by confirmation with the QuantiFERON-TB Gold In-Tube (QFT-GIT) test when targeting preventive therapy in household contacts of patients with tuberculosis. We hypothesized that such a strategy should narrow the target population compared with the standard TST-based strategy without increasing the risk of subsequent active tuberculosis.
METHODS

Study Oversight
This was an investigator-initiated, randomized, open-label, controlled clinical trial that we conducted at 12 public hospitals in Spain. The aim of the study was to test the noninferiority of a sequential strategy of TST followed by QFT-GIT as a confirmatory test against a standard TST-alone strategy when targeting preventive therapy for household contacts of patients with tuberculosis.
The An independent data monitoring committee, the Central Clinical Research Unit in Clinical Trials (UCICEC), had access to all data and oversaw the trial. The Clinical Trials and Statistical Unit at Bellvitge University Hospital-IDIBELL downloaded and analyzed the data contained in the electronic case report forms following the data analysis plan. The first 2 authors (L. M. and M. S.) interpreted the analysis and wrote the first draft of the manuscript. All authors reviewed and approved the final version of the manuscript.
Participants
Participants were considered eligible if they were healthy adult (≥18 years) household contacts of patients with pulmonary or laryngeal tuberculosis and if they provided written informed consent. Contacts whose index case finally had either no culture-confirmed tuberculosis or a multiresistant strain were withdrawn from the study. Exclusion criteria included any immunosuppressive conditions and previous diagnosis of tuberculosis infection. Details are provided in the protocol, which is available in the Supplementary Material.
Randomization and Procedures
After excluding active tuberculosis by clinical assessment and chest X-ray, participants were randomly allocated to either a TST-alone strategy (the TST arm) or a 2-step TST/QFT-GIT strategy (the TST/QTF arm). Randomization was stratified by center in a 1:1 allocation ratio using a computer-generated randomization list integrated into the electronic case report forms. None of the investigators could access the list, which was kept by the UCICEC. Participants allocated to the TST/QFT arm were first tested with TST, and responders (≥5 mm) underwent a QFT-GIT test for confirmation. Diagnosis of tuberculosis infection was based on the QFT-GIT result. By contrast, diagnosis of tuberculosis infection was based only on the TST result in the TST arm. Participants with negative TST or QFT-GIT results, who had been tested 2 months before the last contact with the index case, also underwent a 2nd test 8 weeks later ( Figure 1 ). All contacts diagnosed with tuberculosis infection were given 300 mg of isoniazid daily for 6 months or 600 mg of rifampicin daily for 4r months if they did not tolerate isoniazid or if the related index case's culture yielded an isoniazid-resistant strain. The safety and tolerability of preventive therapy were assessed on the basis of symptoms or signs during treatment (clinical assessment and blood tests at baseline and after 1 and 3 months of treatment and whenever patients presented with new symptoms suggestive of drug toxicity). Adherence was measured at each appointment as follows: by detection of N-acetyl isoniazid in the urine, using the Eidus-Hamilton test [12] , for isoniazid; by the orange color of urine in case of rifampicin; and by returned pill count in each visit. Development of active tuberculosis was assessed by clinical evaluation at each visit and with a chest X-ray at 24 months. When there was clinical suspicion of tuberculosis, respiratory samples were taken for smear stain and culture, and chest X-rays were taken. Follow-up visits were scheduled twice a year for 2 years, irrespective of whether participants received preventive therapy (for full details, see the protocol in Supplementary Material).
Endpoints
The primary study endpoint was the proportion of contacts who developed active tuberculosis during the 24 months after randomization. Diagnosis of active tuberculosis was considered definitive if Mycobacterium tuberculosis was isolated in clinical samples, highly probable if there were compatible clinical data and a positive molecular test in respiratory samples or sterile fluids without positive culture, or probable if there were suggestive clinical and radiographic signs without microbiological confirmation and a favorable response to specific therapy. Strains of secondary tuberculosis cases were matched with those of their index case through mycobacterial interspersed repetitive unitsvariable number of tandem repeats (MIRU-VNTR), which was performed by amplifying the 24 MIRU-VNTR loci as described elsewhere [13] . The secondary endpoint was the proportion of contacts diagnosed with tuberculosis infection.
Statistical Analysis
We designed the trial to assess the noninferiority of the TST/ QFT arm with respect to the TST arm for preventing development of active tuberculosis. Noninferiority was defined as the upper limit of the 1-sided, 97.5% confidence interval (CI) of the difference in tuberculosis incidence between the TST/QFT and the TST arms being <1.5 percentage points. Based on an expected 0.5% risk of progression to active disease within the first 2 years after the randomization, 348 patients was the number of contacts required in each group to achieve a power of 80% to demonstrate the noninferiority hypothesis. To account for a possible 20% patient loss to follow-up in each group, we planned to enroll 870 contacts overall. This sample size was also sufficient to detect a minimum expected effect size of 10% reduction in the proportion of tuberculosis infection diagnosis, assuming a TST positive rate of 45%.
Prespecified subgroup analyses were performed according to Bacillus Calmette-Guérin (BCG) vaccination status.
We performed both modified intention-to-treat and per-protocol analyses. The modified intention-to-treat population included all participants who completed the allocated diagnostic strategy and had at least 1 follow-up assessment. The per-protocol population was restricted to participants who adhered to the clinical trial instructions as established in the protocol in terms of preventive therapy completion, proven adherence, and schedule punctuality. The protocol specified an interim analysis 2 years after the inclusion of the 400th patient, and we established that the trial would stop if the lower 97.5% CI for the estimated incidence of tuberculosis was not strictly to the left of the noninferiority margin. After reviewing the interim analysis, the data and safety monitoring committee recommended continuing the study as planned.
The baseline characteristics and outcome measures were compared by the χ 2 test for categorical variables and Student t test or nonparametric Mann-Whitney U test for continuous variables, as appropriate. The incidence of active tuberculosis was reported as the cumulative incidence and incidence rate (per 100 000 person-years). All statistical analyses were carried out with R (version 3.2.5 for Windows).
RESULTS
Study Population
From September 2010 to February 2014, we enrolled 871 subjects in the study: of these, 438 were allocated to the TST arm and 433 were allocated to the TST/QFT arm. After excluding 79 (9.1%) participants, 792 (90.9%) were included in the modified intention-to-treat analysis, and 482 (55.3%) qualified for the per-protocol analysis ( Figure 2 ). The study ended in February Figure 1 . Overview of the diagnostic strategies. *Negative responders were tested again (after 8 weeks) so as to avoid the window period. Only if their first appointment was >2 months after their last contact with the index case was there no need for a second test. Indeterminate QuantiFERON-TB (QFT) results were supposed to be repeated, and excluded if they were indeterminate in a 2nd QFT test. Abbreviations: QFT, QuantiFERON-TB; TST, tuberculin skin test.
2016 when the last recruited patient attended the last follow-up visit. Both arms were well balanced in terms of baseline demographic characteristics, relationship with the index case, and clinical features of the index cases (Table 1) .
Efficacy
Development of Active Tuberculosis
During the follow-up period, 6 contacts developed active tuberculosis, 4 in the TST arm and 2 in the TST/QFT arm. All 6 cases occurred before the 6th month from their baseline appointment (see full details of the tuberculosis cases in Table 2 ). By the modified intention-to-treat analysis, the cumulative incidences of active tuberculosis were 0.99% (97.5% CI, .34%-2.85%) and 0.51% (97.5% CI, .12%-2.17%) in the TST and the TST/QFT arms, respectively, giving a difference in the tuberculosis incidence rate of −0.48 (97.5% CI, −1.86 to 0.90). The results of the per-protocol analysis were consistent with of the modified intention-to-treat analysis, giving a cumulative incidence of active tuberculosis of 1.67% (97.5% CI, .58%-4.76%) and 0.82% (97.5% CI, .19%-3.45%) in the TST and the TST/QFT arms, respectively; the difference in TB incidence rate was −0.85 (97.5% CI, −3.14 to 1.43) ( Figure 3 ; Table S1 in the Supplementary Material). Three of the 6 active tuberculosis cases in the trial were culture-confirmed, and MIRU-VNTR-based genotyping analysis showed identical patterns between their isolates and those from their respective index cases.
Diagnosis of Tuberculosis Infection
In the modified intention-to-treat analysis, tuberculosis infection was diagnosed in 263 of 403 contacts (65.3%) in the TST arm and 164 of 389 contacts (42.2%) in the TST/QFT arm, giving a difference of 23.1% (95% CI, 16.4%-30.0%). In the per-protocol analysis, 155 of 239 (64.9%) and 104 of 243 (42.8%) contacts were diagnosed with tuberculosis infection in the TST and TST/QFT arms, respectively, giving a difference of 22.1% (95% CI, 13.5%-30.9%). See Figure S1 in the Supplementary Material for more detail. When the modified intention-to-treat analysis was stratified for BCG vaccination status, differences in TB infection diagnoses (between the TST and the TST/QTF arms) of 34.5% (95% CI, 22.5%-46.5%) among BCG-vaccinated contacts and 19.5% (95% CI, 10.9%-28.0%) among non-BCG-vaccinated contacts were found. When the per-protocol analysis was stratified for BCG vaccination status, differences of 31.9% (95% CI, 16.9%-47.0%) among BCG-vaccinated contacts and 18.9% (95% CI, 7.77%-30.1%) among non-BCG-vaccinated contacts were found ( Figure 4A and B) . After adjusting for contagiousness of the index case (sputum smear status and cavitation on chest X-ray), time (cumulative hours per week), and degree of exposure (intimate vs frequent) as covariates, assignation to the TST/ QFT arm remained an independent predictor of reduction in the proportion of diagnosed tuberculosis infections (Supplementary  Appendix and Supplementary Tables S2 and S3 ).
Safety
We included 869 subjects in the safety analysis. There were 54 adverse events in 49 patients (n = 28 and n = 21 for the TST and TST/QFT arms, respectively; P = .40). Of the 429 subjects who were given preventive therapy, 42 (9.8%) experienced treatment-related adverse events, the most frequent being liver toxicity related to isoniazid (n = 28 events; 6.8%). Details of these adverse events are provided in the Supplementary Appendix and Supplementary Table S4 .
DISCUSSION
In this trial, we demonstrated that using the QFT-GIT as a confirmatory test following a positive TST for targeting preventive therapy in household contacts of patients with tuberculosis is not inferior to a TST-alone strategy for the prevention of subsequent active tuberculosis, and it provides the advantage of reducing the number of preventive treatments. According to the World Health Organization, detection and treatment of tuberculosis infection by contact investigation to identify recently exposed people is a main goal of the global strategy to eliminate tuberculosis in low-incidence countries by 2035 [14] . Therefore, optimizing the screening strategies and promoting compliance with preventive therapy schemes are essential. Since their introduction, IGRAs have been increasingly used for screening adults who had contact with patients with tuberculosis. However, a lack of compelling evidence for their superiority over TST has led to diversity in the recommendations given in guidelines and position statements, which have been based on reasons other than the evidence-based balance between the benefits and harms of the tests and strategies [15] [16] [17] [18] [19] [20] . Some guidelines favor the use of either the TST or an IGRA [15, 16, 18] , whereas others recommend primary testing with the TST and only retesting TST reactors with an IGRA [17, 19, 20] . In a systematic review, the sequential strategy seemed to be the most cost-effective in tuberculosis contact studies [21] .
The 2-step approach, aimed at reducing false-positive TST results-especially in BCG-vaccinated individuals-is supported by both observational studies [10, 11, 22, 23] and favorable cost-effectiveness analyses in low-incidence countries [24, 25] .
A large German study that tested close contacts of patients with tuberculosis showed a substantial reduction in the number of diagnoses of tuberculosis infection with QFT-GIT (17%) compared with the TST at a cut-off of 10 mm (31%), and none of the untreated contacts with TST-positive and QFT-GIT-negative results developed tuberculosis after at least 2 years of follow-up [22] . Similarly, 35% of TST-positive contacts in a French study had a positive QFT-GIT, and only 1 contact (0.2%) with a TSTpositive and QFT-GIT-negative result developed active tuberculosis after 3 years of follow-up [23] . In a study of high school students in South Korea who had contact with patients with tuberculosis, the addition of QFT-Gold (QFT-G) as a confirmatory test for the TST reduced the number of preventive treatments, with none of the TST-positive/QFT-G-negative contacts progressing to active disease [11] . In a Dutch study using an IGRA to confirm TST results, 3 of 9 foreign-born contacts who subsequently developed active tuberculosis were missed by the QFT-GIT (they were TST-positive but QFT-GIT-negative) [10] . Now, for the first time, a randomized controlled clinical trial provides solid evidence showing the benefit of including IGRA tests to avert overdiagnosis and avoidable treatments when testing adult contacts of patients with tuberculosis in a low-incidence setting. Our results showed that for every 5 contacts screened with the 2-step strategy, 1 unnecessary preventive treatment could be avoided. This benefit was achieved not only in the subset of BCG-vaccinated contacts, in which it may be expected, but also among nonvaccinated contacts, probably in relation with exposure to nontuberculous mycobacteria. Several analyses, including those of contacts with the highest risk profiles (ie, intimate contacts of smear-positive index cases who presented with cavitation on chest X-ray), still showed a significant reduction in the proportion of tuberculosis infection diagnosis when screened with the 2-step approach. Under both arms, 6 patients developed active tuberculosis during the 2-year follow-up period. Three of them, who developed active disease during the screening process, could be considered as prevalent cases, whereas the other three TST-arm-assigned cases should be deemed as incident cases.
Our results provide reassurance that using QFT-GIT in tuberculosis contact tracing is effective and safe. However, we have not established whether this is the most convenient strategy or whether the QFT-GIT should entirely replace TST in terms of cost-effectiveness. In the setting of well-selected, high-risk contacts, which implies a high estimated pretest probability; screening with the QFT-GIT alone might be a more cost-effective option, despite the higher unit cost. Conversely, if there is low pretest probability, performing the QFT-GIT in TST reactors would probably be most convenient because this strategy would reduce the overall number of QFT-GIT tests and, therefore, testing costs.
Our trial has weaknesses that deserve further comment. First, we did not include a third arm of screening with the QFT-GIT alone, which would have helped us to establish whether using QFT-GIT as a confirmatory test or using it to replace the TST is a better strategy. Unfortunately, the necessary size of the sample was prohibitive and could not be achieved in a reasonable period. Second, the sequential strategy might pose 2 problems: On the one hand, it prevented us from estimating the proportion of TST-negative/QFT-GIT-positive results. However, these results would be extremely infrequent in healthy adults and probably would change to a positive TST/positive IGRA after the window period. On the other hand, the boosting effect of a preceding TST could lead to an increase in the number of positive on subsequent QFT-GIT results. However, this effect is only considered in those subjects converting from negative to a positive TST and then tested with QFT-GIT. In fact, in our study, the occurrence of such potential boosting effect would mean that there would be even fewer "real" diagnoses of tuberculosis infection in the TST/QFT arm as compared with the TST arm, favoring our hypothesis.
Third, the 2-year observational period may have been insufficient to assess the real risk of developing tuberculosis. Indeed, this is a common limitation of most contact-tracing studies looking at the risk of tuberculosis development. However, because the first 2 years after recent exposure constitute the period of highest risk [2] , our results are comparable with those of previous observational studies.
We concluded that in low-incidence settings of tuberculosis, using QFT-GIT to confirm positive TST reactors results in a significant reduction of tuberculosis infection diagnoses and preventive therapy prescriptions without increasing the risk of active disease.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Notes
Disclaimer. Alere, the Spanish distributor of QFT-GIT (Cellestis Limited, currently owned by Qiagen) provided the participating centers with QFT-GIT blood-collecting tubes, but had no role in the design of the trial, data analysis, or interpretation of the results. Proportion of participants with tuberculosis infection in the modified intention-totreat (A) and in the per-protocol (B) populations. *Differences between arms for both modified intention-to-treat and per-protocol analyses (Global P < .001; BCGvaccinated, P < .001; non-BCG-vaccinated, P = .001). Abbreviations: BCG, Bacillus Calmette-Guérin; QFT, QuantiFERON-TB; TST, tuberculin skin test.
